Thank you to everyone across the healthcare landscape who worked tirelessly to achieve our recent CAR T cell therapy FDA approval, helping to better serve blood cancer patients with unmet needs. This milestone was made possible by the dedication of people both inside and outside of BMS. In particular, we want to thank the patients and HCPs who participated in the clinical trials, the advocacy groups that supported the patient community, and the many BMS team members who worked to achieve this approval.